Published in Hypoxia (Auckl) on November 11, 2015
Multiple Roles of Angiopoietin-Like 4 in Osteolytic Disease. Front Endocrinol (Lausanne) (2017) 0.75
HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab (2006) 13.22
HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab (2006) 10.14
HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell (2003) 9.12
Genetic regulation of osteoclast development and function. Nat Rev Genet (2003) 7.94
Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem (2008) 7.71
Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell (2010) 7.20
HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell (2007) 6.31
Microdomains with high Ca2+ close to IP3-sensitive channels that are sensed by neighboring mitochondria. Science (1993) 6.29
Role of calcium ions in regulation of mammalian intramitochondrial metabolism. Physiol Rev (1990) 5.94
5'-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments. Mol Cell Biol (2006) 4.28
Transcription factor HIF-1 is a necessary mediator of the pasteur effect in mammalian cells. Mol Cell Biol (2001) 4.03
The hypoxia-inducible factor alpha pathway couples angiogenesis to osteogenesis during skeletal development. J Clin Invest (2007) 3.76
Oxygen-dependent regulation of mitochondrial respiration by hypoxia-inducible factor 1. Biochem J (2007) 2.72
Activation of the hypoxia-inducible factor-1alpha pathway accelerates bone regeneration. Proc Natl Acad Sci U S A (2008) 2.65
FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. Radiology (2001) 2.46
Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J Exp Med (1999) 2.13
Synovial fluid pH, lactate, oxygen and carbon dioxide partial pressure in various joint diseases. Arthritis Rheum (1971) 2.11
Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J Rheumatol (1998) 1.97
The human osteoclast precursor circulates in the monocyte fraction. Endocrinology (1996) 1.89
Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid joint. Arthritis Rheum (1984) 1.85
Prolyl hydroxylase inhibitors increase neoangiogenesis and callus formation following femur fracture in mice. J Orthop Res (2009) 1.76
A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology (1998) 1.75
Raised serum vascular endothelial growth factor levels are associated with destructive change in inflammatory arthritis. Arthritis Rheum (2001) 1.74
HIF1α is required for osteoclast activation by estrogen deficiency in postmenopausal osteoporosis. Proc Natl Acad Sci U S A (2013) 1.67
Evidence for the presence of a proton pump of the vacuolar H(+)-ATPase type in the ruffled borders of osteoclasts. J Cell Biol (1990) 1.62
RANKL-mediated reactive oxygen species pathway that induces long lasting Ca2+ oscillations essential for osteoclastogenesis. J Biol Chem (2010) 1.58
Hypoxia triggers AMPK activation through reactive oxygen species-mediated activation of calcium release-activated calcium channels. Mol Cell Biol (2011) 1.54
Osteoclast size is controlled by Fra-2 through LIF/LIF-receptor signalling and hypoxia. Nature (2008) 1.52
Hypoxia is a major stimulator of osteoclast formation and bone resorption. J Cell Physiol (2003) 1.47
Dimethyloxalylglycine prevents bone loss in ovariectomized C57BL/6J mice through enhanced angiogenesis and osteogenesis. PLoS One (2014) 1.47
Prognostic factors and diagnostic criteria in early rheumatoid arthritis. Scand J Rheumatol Suppl (1985) 1.45
Intermittent hypoxia effect on osteoclastogenesis stimulated by neuroblastoma cells. PLoS One (2014) 1.42
Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors. Eur J Med Chem (2012) 1.41
18F-FDG kinetics and gene expression in giant cell tumors. J Nucl Med (2004) 1.29
Role of HIF-1alpha in skeletal development. Ann N Y Acad Sci (2010) 1.27
FoxO proteins restrain osteoclastogenesis and bone resorption by attenuating H2O2 accumulation. Nat Commun (2014) 1.23
Annexin V staining due to loss of membrane asymmetry can be reversible and precede commitment to apoptotic death. Exp Cell Res (1999) 1.18
The a-subunit of the V-type H+-ATPase interacts with phosphofructokinase-1 in humans. J Biol Chem (2003) 1.18
Hypoxia-inducible factor is expressed in giant cell tumour of bone and mediates paracrine effects of hypoxia on monocyte-osteoclast differentiation via induction of VEGF. J Pathol (2008) 1.17
Intracellular machinery for matrix degradation in bone-resorbing osteoclasts. J Bone Miner Res (2004) 1.15
New regulation mechanisms of osteoclast differentiation. Ann N Y Acad Sci (2011) 1.14
Hypoxia-inducible factor regulates osteoclast-mediated bone resorption: role of angiopoietin-like 4. FASEB J (2010) 1.05
Acute hypoxia and osteoclast activity: a balance between enhanced resorption and increased apoptosis. J Pathol (2009) 1.04
Comparative study of protein and mRNA expression during osteoclastogenesis. Proteomics (2005) 1.02
Osteoclast precursors display dynamic metabolic shifts toward accelerated glucose metabolism at an early stage of RANKL-stimulated osteoclast differentiation. Cell Physiol Biochem (2007) 1.01
AMP kinase acts as a negative regulator of RANKL in the differentiation of osteoclasts. Bone (2010) 1.00
Regulation of osteoclastic bone resorption by glucose. Biochem Biophys Res Commun (1997) 1.00
Hypoxia induces giant osteoclast formation and extensive bone resorption in the cat. Calcif Tissue Int (2006) 0.99
Bone metastases: molecular mechanisms and novel therapeutic interventions. Med Res Rev (2010) 0.99
Mitochondrial permeability transition and swelling can occur reversibly without inducing cell death in intact human cells. Exp Cell Res (1999) 0.99
THE FINE STRUCTURE OF BONE CELLS. J Biophys Biochem Cytol (1961) 0.99
Metabolic regulation of osteoclast differentiation and function. J Bone Miner Res (2013) 0.98
Pyruvate dehydrogenase kinase 4 expression is synergistically induced by AMP-activated protein kinase and fatty acids. Cell Mol Life Sci (2009) 0.97
The systemic nature of chronic lung disease. Clin Chest Med (2014) 0.96
Effects of soluble cobalt and cobalt incorporated into calcium phosphate layers on osteoclast differentiation and activation. Biomaterials (2008) 0.96
Hypoxia stimulates osteoclast formation from human peripheral blood. Cell Biochem Funct (2010) 0.95
Role of mitochondrial reactive oxygen species in osteoclast differentiation. Ann N Y Acad Sci (2010) 0.95
Immunologic stimulation of mast cells leads to the reversible exposure of phosphatidylserine in the absence of apoptosis. Int Arch Allergy Immunol (2000) 0.95
Positive regulation of osteoclastic differentiation by growth differentiation factor 15 upregulated in osteocytic cells under hypoxia. J Bone Miner Res (2012) 0.93
2-Methoxyestradiol suppresses osteolytic breast cancer tumor progression in vivo. Cancer Res (2007) 0.92
Genistein prevents bone resorption diseases by inhibiting bone resorption and stimulating bone formation. Biol Pharm Bull (2003) 0.92
Survival of cultured cells after functional and structural disorganization of plasma membrane by bacterial haemolysins and phospholipases. Toxicon (1983) 0.91
ATPase pumps in osteoclasts and osteoblasts. Int J Biochem Cell Biol (2002) 0.91
Differential regulation of HIF-mediated pathways increases mitochondrial metabolism and ATP production in hypoxic osteoclasts. J Pathol (2013) 0.91
The proteasome inhibitor bortezomib drastically affects inflammation and bone disease in adjuvant-induced arthritis in rats. Arthritis Rheum (2010) 0.89
Hypoxia: how does the monocyte-macrophage system respond to changes in oxygen availability? J Leukoc Biol (2013) 0.88
Hypoxia-mediated mitochondrial stress in RAW264.7 cells induces osteoclast-like TRAP-positive cells. Ann N Y Acad Sci (2007) 0.88
Angiopoietin-like 4 is over-expressed in rheumatoid arthritis patients: association with pathological bone resorption. PLoS One (2014) 0.87
Reversible phosphatidylserine expression on blood granulocytes related to membrane perturbation but not DNA strand breaks. J Leukoc Biol (2002) 0.87
Prolyl hydroxylase inhibitors protect from the bone loss in ovariectomy rats by increasing bone vascularity. Cell Biochem Biophys (2014) 0.86
Biological agents in management of osteoporosis. Eur J Clin Pharmacol (2014) 0.86
Regulation and enzymatic basis of bone resorption by human osteoclasts. Clin Sci (Lond) (2007) 0.86
New therapeutic targets for cancer bone metastasis. Trends Pharmacol Sci (2015) 0.86
Hypoxia, stem cells and bone tumor. Cancer Lett (2011) 0.86
Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity. Eur J Pharmacol (2006) 0.86
Glucose is a key metabolic regulator of osteoclasts; glucose stimulated increases in ATP/ADP ratio and calmodulin kinase II activity. Biochem Cell Biol (2005) 0.85
Reactive oxygen species and oxidative stress in osteoclastogenesis, skeletal aging and bone diseases. J Bone Miner Metab (2015) 0.85
Hypoxic stress enhances osteoclast differentiation via increasing IGF2 production by non-osteoclastic cells. Biochem Biophys Res Commun (2005) 0.85
Activation of the hypoxia-inducible factor-1 in overloaded temporomandibular joint, and induction of osteoclastogenesis. Biochem Biophys Res Commun (2010) 0.84
Disease modifying and antiangiogenic activity of 2-methoxyestradiol in a murine model of rheumatoid arthritis. BMC Musculoskelet Disord (2009) 0.84
Glucose-dependent regulation of osteoclast H(+)-ATPase expression: potential role of p38 MAP-kinase. J Cell Biochem (2002) 0.83
Hyperbaric oxygen therapy suppresses osteoclast formation and bone resorption. J Orthop Res (2013) 0.83
Hypoxia triggers a HIF-mediated differentiation of peripheral blood mononuclear cells into osteoclasts. Orthod Craniofac Res (2012) 0.83
Inhibition of osteoclastogenesis by prolyl hydroxylase inhibitor dimethyloxallyl glycine. J Bone Miner Metab (2010) 0.82
Inhibition of arthritis by systemic administration of endostatin in passive murine collagen induced arthritis. Ann Rheum Dis (2003) 0.81
Imatinib treatment of seropositive arthritis in a young woman with chronic myeloid leukemia. J Rheumatol (2008) 0.80
Inhibitor of DNA binding/differentiation 2 induced by hypoxia promotes synovial fibroblast-dependent osteoclastogenesis. Arthritis Rheum (2009) 0.79
Imatinib mesylate induces clinical remission in rheumatoid arthritis. Joint Bone Spine (2010) 0.79
Role of 2-methoxyestradiol as inhibitor of arthritis and osteoporosis in a model of postmenopausal rheumatoid arthritis. Clin Immunol (2011) 0.78
Apigenin inhibits osteoblastogenesis and osteoclastogenesis and prevents bone loss in ovariectomized mice. Cytotechnology (2014) 0.78
Enhanced osteoclastogenesis by mitochondrial retrograde signaling through transcriptional activation of the cathepsin K gene. Ann N Y Acad Sci (2015) 0.78
Can we enhance fracture vascularity: What is the evidence? Injury (2014) 0.78
2-methoxyestradiol analogue ENMD-1198 reduces breast cancer-induced osteolysis and tumor burden both in vitro and in vivo. Mol Cancer Ther (2011) 0.78
Effect of CoCl₂ on fracture repair in a rat model of bone fracture. Mol Med Rep (2015) 0.78
Oxygen-sensing PHDs regulate bone homeostasis through the modulation of osteoprotegerin. Genes Dev (2015) 0.78
Reactive oxygen species induce the association of SHP-1 with c-Src and the oxidation of both to enhance osteoclast survival. Am J Physiol Endocrinol Metab (2014) 0.77
Osteoclastic resorptive capacity is suppressed in patients receiving hyperbaric oxygen therapy. Acta Orthop (2014) 0.76
HIF-1α disturbs osteoblasts and osteoclasts coupling in bone remodeling by up-regulating OPG expression. In Vitro Cell Dev Biol Anim (2015) 0.76